Glioblastoma Treatment in India: Advanced GBM Surgery & Multimodal Therapy

What is Glioblastoma (GBM)?

الورم الأرومي الدبقي , also known as glioblastoma multiforme (GBM), is the most aggressive and lethal primary brain tumor in adults. Classified as a WHO Grade IV glioma, it arises from astrocytes — the star-shaped glial cells that support neurons in the brain. Glioblastoma accounts for approximately 15% of all brain tumors and nearly 50% of all malignant primary brain tumors, making it a significant focus of glioblastoma treatment in India and worldwide.

What makes glioblastoma particularly challenging is its highly infiltrative nature. Unlike many other tumors that grow as a distinct mass, GBM cells spread into surrounding healthy brain tissue like roots extending into soil. This diffuse invasion means that even after aggressive surgical removal, microscopic tumor cells remain embedded in functional brain tissue, leading to the high recurrence rates associated with this disease.

Glioblastoma is characterized by several hallmark features that distinguish it from lower-grade brain tumors:

• Rapid proliferation: GBM cells divide at an exceptionally fast rate, with the tumor capable of doubling in size within weeks.
• Neovascularization: The tumor stimulates the formation of new, abnormal blood vessels (angiogenesis) to supply its rapid growth, though these vessels are often leaky and disorganized.
• Central necrosis: Areas of dead tissue (necrosis) within the tumor core, surrounded by actively growing cells, creating a characteristic ring-enhancing appearance on MRI.
• Cellular heterogeneity: GBM contains multiple cell types with different genetic profiles, making it resistant to single-agent therapies.
• Blood-brain barrier disruption: The tumor compromises the blood-brain barrier, leading to surrounding edema (swelling) that contributes to neurological symptoms.

Glioblastoma predominantly affects adults between the ages of 45 and 70, with a slightly higher incidence in men than women. While the exact causes remain largely unknown, established risk factors include prior exposure to ionizing radiation, certain genetic syndromes (such as Li-Fraumeni syndrome and neurofibromatosis type 1), and advancing age. Unlike many cancers, there is no proven link between lifestyle factors and glioblastoma development.

At Spine and Brain India, د. آرون ساروها brings over 20 years of neurosurgical expertise to the treatment of glioblastoma, combining advanced surgical techniques with a comprehensive multimodal approach that offers patients the best possible outcomes within the current understanding of this disease.

Glioblastoma Symptoms & Diagnosis

Glioblastoma symptoms can develop rapidly — often over days to weeks — due to the tumor's aggressive growth pattern. The symptoms are caused by a combination of direct tissue destruction, increased intracranial pressure from the tumor mass and surrounding swelling, and disruption of normal neural pathways. Recognizing these warning signs early is critical, as timely diagnosis and prompt initiation of GBM treatment can significantly impact outcomes.

Warning Signs of Glioblastoma

• Progressive headaches: New-onset headaches that worsen over days to weeks, often most severe in the early morning or upon waking, and may be accompanied by nausea and vomiting due to raised intracranial pressure.
• النوبات: New-onset seizures are the presenting symptom in approximately 20-30% of GBM patients. These may be focal (affecting one body part) or generalized (full-body convulsions).
• Cognitive and personality changes: Memory difficulties, confusion, impaired judgment, personality shifts, and behavioral changes, particularly when the tumor involves the frontal or temporal lobes.
• Focal neurological deficits: Progressive weakness on one side of the body (hemiparesis), numbness, difficulty speaking (aphasia), or visual field loss, depending on the tumor location.
• Nausea and vomiting: Often worse in the morning, caused by increased intracranial pressure that is more pronounced when lying flat during sleep.
• Vision changes: Blurred or double vision, loss of peripheral vision, or papilledema (swelling of the optic nerve) caused by elevated brain pressure.
• Balance and coordination problems: Difficulty walking, unsteadiness, or loss of coordination when the tumor affects the cerebellum or motor pathways.

Diagnostic Evaluation for Glioblastoma

Accurate and rapid diagnosis is essential for initiating timely treatment. The diagnostic workup for suspected glioblastoma includes:

• MRI with gadolinium contrast: The gold standard imaging study for glioblastoma. GBM typically appears as an irregularly enhancing mass with a necrotic (dark) center, surrounding ring enhancement, and extensive surrounding edema (T2/FLAIR hyperintensity). This characteristic appearance is often described as a “ring-enhancing lesion.”
• MR Spectroscopy (MRS): Analyzes the chemical composition of the tumor tissue, showing elevated choline (indicating rapid cell turnover), reduced N-acetylaspartate (NAA, indicating neuronal damage), and a lactate peak (indicating anaerobic metabolism) — findings characteristic of high-grade gliomas.
• MR Perfusion imaging: Measures blood flow within the tumor, with high cerebral blood volume (rCBV) values strongly suggestive of GBM due to its prominent neovascularization.
• Functional MRI (fMRI): Maps critical brain areas for language, motor function, and other essential functions before surgery, enabling the surgeon to plan the safest possible approach to the tumor.
• Diffusion Tensor Imaging (DTI): Visualizes white matter tracts (nerve fiber pathways) around the tumor, helping the surgeon avoid damaging critical connections during resection.
• الأشعة المقطعية: May be the first imaging study in emergency presentations. Shows the mass effect and can detect acute hemorrhage within the tumor.
• Stereotactic biopsy: When the tumor is in a location that makes surgical resection challenging, a needle biopsy guided by imaging is performed to obtain tissue for definitive histopathological diagnosis.
• Molecular testing: After tissue is obtained, molecular analysis for MGMT promoter methylation, IDH mutation status, and other genetic markers is critical for guiding treatment decisions and predicting prognosis.

هام: If you or a loved one is experiencing rapidly progressive headaches, new seizures, or sudden neurological changes, seek urgent evaluation. Early diagnosis of glioblastoma allows for prompt surgical intervention, which is one of the strongest predictors of improved survival. Call +91-7860000705 to schedule an urgent consultation with Dr. Arun Saroha.

Glioblastoma Treatment Options in India

The management of glioblastoma requires an integrated, multimodal approach combining surgery, radiation, and chemotherapy. At Spine and Brain India, Dr. Arun Saroha works closely with radiation oncologists, medical oncologists, and neuro-rehabilitation specialists to deliver a comprehensive treatment plan tailored to each patient's unique clinical situation. India has emerged as a preferred destination for glioblastoma treatment due to the availability of world-class technology, experienced neuro-oncology teams, and significantly lower costs compared to Western countries.

Surgical Resection

Maximal safe surgical resection is the cornerstone of glioblastoma treatment. The primary goal of surgery is to remove as much of the visible tumor as possible while preserving neurological function. Research consistently demonstrates that greater extent of resection (EOR) correlates directly with improved survival outcomes — patients achieving greater than 90% resection show significantly better median survival compared to those with subtotal resection or biopsy alone.

Dr. Arun Saroha employs several advanced surgical techniques to maximize tumor removal while minimizing risk to healthy brain tissue:

• Fluorescence-guided surgery (5-ALA): The patient is given an oral dose of 5-aminolevulinic acid (5-ALA) several hours before surgery. Glioblastoma cells metabolize this compound into protoporphyrin IX, which glows bright pink-violet under blue-violet light. This allows the surgeon to visualize tumor margins in real time, distinguishing malignant tissue from normal brain with remarkable accuracy. Studies show that 5-ALA-guided surgery achieves complete resection in up to 65% of patients, compared to approximately 36% with conventional microsurgery alone.
• Neuronavigation (image-guided surgery): A frameless stereotactic navigation system uses preoperative MRI data to create a three-dimensional map of the brain and tumor. During surgery, the system tracks the position of surgical instruments in real time relative to this map, providing millimeter-level accuracy. This technology is especially valuable for tumors located near eloquent brain areas or deep within the brain parenchyma.
• Awake craniotomy: For glioblastomas located in or near language, motor, or sensory areas (eloquent cortex), awake craniotomy allows the patient to remain conscious during the critical phase of tumor removal. The patient performs language tasks, moves limbs, or responds to stimuli while the surgeon maps functional brain areas using direct cortical stimulation. This technique enables more aggressive resection in eloquent areas while dramatically reducing the risk of permanent neurological deficits.
• Intraoperative MRI (iMRI): Real-time MRI scanning during surgery allows the surgeon to assess the extent of resection before closing, identifying any residual tumor that can be safely removed. This technology has been shown to significantly improve rates of gross total resection.
• Intraoperative ultrasound: Provides real-time imaging during surgery to help guide tumor removal and identify residual disease, particularly useful when iMRI is not available.
• Microsurgical technique: High-powered surgical microscopes with excellent illumination and magnification allow precise dissection along tumor-brain interfaces, preserving critical blood vessels and neural structures.

العلاج الإشعاعي

Radiation therapy is a critical component of glioblastoma treatment, typically beginning 2-4 weeks after surgery to allow adequate wound healing. The standard protocol involves external beam radiation therapy delivering a total dose of 60 Gray (Gy) administered in 30 fractions over 6 weeks. This fractionated approach maximizes tumor cell kill while allowing normal brain tissue time to repair between treatments.

Advanced radiation techniques used for GBM treatment in India include:

• Intensity-Modulated Radiation Therapy (IMRT): Shapes the radiation beam to conform precisely to the tumor cavity and surrounding at-risk areas, reducing radiation exposure to adjacent healthy brain tissue. IMRT is particularly important for tumors near sensitive structures such as the optic nerves, brainstem, or hippocampi.
• 3D Conformal Radiation Therapy (3D-CRT): Uses CT and MRI-based planning to deliver radiation beams that match the three-dimensional shape of the tumor bed, ensuring adequate coverage while minimizing collateral damage.
• Volumetric Modulated Arc Therapy (VMAT): An advanced form of IMRT that delivers radiation continuously as the machine rotates around the patient, resulting in shorter treatment times and potentially more uniform dose distribution.

For elderly patients (over 70) or those with poor performance status, hypofractionated radiation protocols — delivering higher doses per fraction over a shorter course (e.g., 40 Gy in 15 fractions over 3 weeks) — have been shown to provide comparable survival benefits with reduced treatment burden.

Chemotherapy (Temozolomide)

Temozolomide (TMZ) is the standard chemotherapy agent for glioblastoma and the cornerstone of the Stupp protocol. It is an oral alkylating agent that crosses the blood-brain barrier effectively, making it uniquely suited for treating brain tumors. Temozolomide works by adding methyl groups to DNA, causing damage that leads to tumor cell death.

The effectiveness of temozolomide is closely linked to the MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation status of the tumor. MGMT is a DNA repair enzyme that can reverse the damage caused by temozolomide. Approximately 35-45% of glioblastomas have a methylated (silenced) MGMT promoter, meaning the repair enzyme is not produced, making these tumors significantly more sensitive to temozolomide. Patients with MGMT-methylated tumors typically achieve median survival of 21-23 months, compared to 12-15 months for unmethylated tumors.

Temozolomide is administered in two phases:

• Concurrent phase: 75 mg/m² daily for 42 consecutive days alongside radiation therapy, with prophylactic anti-nausea medication and monitoring for lymphocyte depletion (requiring Pneumocystis pneumonia prophylaxis).
• Adjuvant phase: 150-200 mg/m² for 5 days of each 28-day cycle, for 6-12 cycles. The dose is escalated from 150 mg/m² in the first cycle to 200 mg/m² in subsequent cycles if blood counts remain adequate.

Targeted Therapy & Immunotherapy

While the Stupp protocol remains the standard of care, several additional therapeutic approaches are available or under investigation for glioblastoma:

• Bevacizumab (Avastin): An anti-angiogenic monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting the tumor's blood supply. Bevacizumab is approved for recurrent glioblastoma and has been shown to reduce tumor-related edema, decrease steroid requirements, and improve progression-free survival. While it may not significantly extend overall survival, it can meaningfully improve quality of life and neurological function in recurrent disease.
• Immune checkpoint inhibitors: Drugs such as nivolumab and pembrolizumab, which have shown remarkable success in other cancers, are being actively studied in glioblastoma clinical trials. While initial results have been modest, combination approaches and patient selection based on tumor mutational burden are being explored.
• Dendritic cell vaccines: Personalized vaccines created from the patient's own immune cells, trained to recognize and attack glioblastoma-specific antigens. Several clinical trials are showing encouraging early results.
• CAR-T cell therapy: Chimeric antigen receptor T-cell therapy, where the patient's T cells are engineered to target specific proteins on glioblastoma cells (such as EGFRvIII), is in clinical trials with promising preliminary data.
• Lomustine (CCNU): A nitrosourea chemotherapy agent used in combination with other treatments, particularly for recurrent GBM or in patients with MGMT-methylated tumors.

Tumor Treating Fields (TTFields/Optune)

Tumor Treating Fields (TTFields), marketed as the Optune device, represent a newer treatment modality for glioblastoma. TTFields deliver low-intensity, intermediate-frequency (200 kHz) alternating electric fields to the tumor through transducer arrays placed on the patient's shaved scalp. These electric fields disrupt cell division (mitosis) by interfering with the alignment of charged cellular components during cell division, leading to cell death specifically in rapidly dividing tumor cells while largely sparing normal brain cells that divide much more slowly.

The landmark EF-14 clinical trial demonstrated that adding TTFields to maintenance temozolomide after chemoradiation improved median overall survival from 16 months to 20.9 months, with the 5-year survival rate improving from 5% to 13%. TTFields are most effective when worn for at least 18 hours per day. While the device requires continuous use and commitment from the patient, it has a relatively mild side effect profile, with the most common adverse effect being skin irritation at the transducer array sites.

TTFields are currently approved as an adjunct to maintenance temozolomide for newly diagnosed glioblastoma and as monotherapy for recurrent glioblastoma. Availability and cost continue to evolve, and Dr. Saroha can advise patients on whether TTFields may be an appropriate addition to their treatment plan.

The Stupp Protocol: Standard of Care for GBM

ال Stupp protocol, established through a landmark 2005 clinical trial led by Dr. Roger Stupp, revolutionized glioblastoma treatment and remains the gold standard worldwide. This protocol demonstrated that combining temozolomide chemotherapy with radiation therapy significantly improved survival compared to radiation therapy alone. The original trial showed a median survival improvement from 12.1 months to 14.6 months, and the 2-year survival rate improved from 10.4% to 26.5%.

The Stupp protocol consists of three sequential phases:

• Phase 1 — Maximal safe surgical resection: The most complete tumor removal that can be achieved without causing unacceptable neurological harm. Ideally, gross total resection (removal of all visible tumor on MRI) is the goal, with studies showing that resection of greater than 98% of the enhancing tumor provides optimal survival benefit.
• Phase 2 — Concurrent chemoradiation (6 weeks): Beginning 2-4 weeks after surgery, the patient receives 60 Gy of focused radiation in 30 daily fractions (Monday through Friday for 6 weeks) with simultaneous daily oral temozolomide at 75 mg/m². During this phase, patients require regular blood count monitoring and receive prophylactic trimethoprim-sulfamethoxazole to prevent Pneumocystis pneumonia.
• Phase 3 — Adjuvant temozolomide (6-12 cycles): After a 4-week break following chemoradiation, patients begin adjuvant temozolomide at 150-200 mg/m² for 5 consecutive days of each 28-day cycle. Treatment continues for a minimum of 6 cycles and may be extended to 12 cycles depending on tolerance and response. Blood counts are monitored before each cycle.

Dr. Arun Saroha coordinates each phase of the Stupp protocol with a dedicated team of radiation oncologists and medical oncologists at Max Super Speciality Hospital, ensuring seamless transitions between treatment phases and proactive management of any side effects.

Glioblastoma Surgery Success Rates & Prognosis

Glioblastoma remains one of the most challenging cancers to treat, and it is important for patients and families to have an honest understanding of what current treatments can achieve. While a cure is not yet possible for most patients, significant progress has been made in extending survival and maintaining quality of life. Prognosis depends on several key factors, and understanding these can help guide treatment decisions.

It is worth noting that these are population-level statistics, and individual outcomes can vary significantly. Some patients with favorable molecular profiles, maximal resection, and good response to treatment achieve survival well beyond the median. Dr. Saroha takes a personalized approach to each case, considering all prognostic factors to develop the most effective treatment strategy while maintaining honest and compassionate communication with patients and families about expectations.

Cost of Glioblastoma Treatment in India

One of the key reasons patients from around the world choose India for glioblastoma treatment is the significant cost advantage without compromising on quality of care. Treatment at Max Super Speciality Hospital under Dr. Arun Saroha is performed with the same advanced technology and protocols used at leading cancer centers worldwide, but at a fraction of the cost. Below is a detailed breakdown of typical treatment costs:

These costs are approximately أقل بنسبة 60-80٪ than equivalent treatment in the United States, United Kingdom, or Europe. For international patients, our team provides comprehensive support including cost estimates before arrival, assistance with medical visas, accommodation arrangements, and coordination of all treatment logistics. The total first-year cost of ₹8-15 lakh (approximately $10,000-$18,000 USD) compares favorably with $150,000-$300,000+ for similar treatment in the United States.

Costs may vary based on the specific hospital room category chosen, any complications requiring extended ICU stay, the need for additional procedures such as a VP shunt for hydrocephalus, and whether targeted therapies like bevacizumab are added to the treatment plan. Dr. Saroha's team provides a detailed cost estimate after reviewing the patient's medical reports.

Why Choose Dr. Arun Saroha for Glioblastoma Surgery?

Glioblastoma surgery demands the highest level of neurosurgical skill, and the choice of surgeon directly impacts the extent of resection achievable — which is one of the most important modifiable prognostic factors. Dr. Arun Saroha brings a unique combination of experience, technology, and patient-centered care to every glioblastoma case:

• 20+ years of neurosurgical experience with extensive expertise in complex brain tumor resection, including tumors in challenging locations such as the motor strip, speech areas, basal ganglia, and brainstem.
• Advanced surgical technology: Routine use of fluorescence-guided surgery (5-ALA), intraoperative neuronavigation, awake craniotomy techniques, and intraoperative neurophysiological monitoring to maximize resection while preserving function.
• Integrated multidisciplinary team: Seamless coordination with radiation oncologists, medical oncologists, neuro-radiologists, pathologists, and rehabilitation specialists at Max Super Speciality Hospital, ensuring comprehensive care from diagnosis through long-term follow-up.
• Commitment to maximal safe resection: Dr. Saroha's surgical philosophy prioritizes achieving the greatest extent of resection that can be performed without causing new neurological deficits, as research consistently shows this approach optimizes survival outcomes.
• Compassionate, honest communication: Glioblastoma is a devastating diagnosis, and Dr. Saroha is committed to providing patients and families with clear, honest information about the disease, treatment options, and realistic expectations, empowering them to make informed decisions.
• International patient support: A dedicated team assists international patients with visa facilitation, airport transfers, accommodation, language interpreters, and ongoing communication throughout the treatment journey.

Related Services & Resources

Learn more about our comprehensive neurosurgical services:

• جراحة أورام المخ في الهند — comprehensive overview of all brain tumor types and surgical approaches
• جراحة الدماغ في الهند — full range of neurosurgical procedures available
• أفضل جراح أعصاب في دلهي لماذا يثق المرضى بالدكتور أرون ساروها